Literature DB >> 16359588

Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study.

Volker Mall1, Florian Heinen, Andrea Siebel, Christoph Bertram, Ulrich Hafkemeyer, Jörg Wissel, Steffen Berweck, Fritz Haverkamp, Günter Nass, Leo Döderlein, Nico Breitbach-Faller, Wilhelm Schulte-Mattler, Rudolf Korinthenberg.   

Abstract

Adductor spasticity in children with cerebral palsy (CP) impairs motor function and development. In a placebo-controlled, double-blind, randomized multicentre study, we evaluated the effects of botulinum toxin A(BTX-A) in 61 children (37 males, 24 females; mean age 6 years 1 month [SD 3y 1mo]) with CP (leg-dominated tetraparesis, n=39; tetraparesis, n=22; GMFCS level I, n=3; II, n=6; III, n=17; IV, n=29; V, n=6). Four weeks after treatment, a significant superiority of BTX-A was observed in the primary outcome measure (knee-knee distance 'fast catch', p=0.002), the Ashworth scale (p=0.001), and the Goal Attainment Scale (p=0.037).

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16359588     DOI： 10.1017/S0012162206000041

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN： 0012-1622            Impact factor:   5.449


  17 in total

Review 1.  AbobotulinumtoxinA: A Review in Pediatric Lower Limb Spasticity.

Authors:  Yahiya Y Syed
Journal:  Paediatr Drugs       Date:  2017-08       Impact factor: 3.022

2.  Effectiveness of Multilevel Botulinum Toxin A Injection with Integrated Treatment Program on Spasticity Reduction in Non-Ambulatory Young Children with Cerebral Palsy.

Authors:  Sebahat Aydil; Fatma Merih Akpinar; Evren Akpinar; Kubilay Beng; Mehmet Firat Yagmurlu
Journal:  Med Princ Pract       Date:  2019-03-06       Impact factor: 1.927

Review 3.  A systematic review to investigate the measurement properties of goal attainment scaling, towards use in drug trials.

Authors:  Charlotte M W Gaasterland; Marijke C Jansen-van der Weide; Stephanie S Weinreich; Johanna H van der Lee
Journal:  BMC Med Res Methodol       Date:  2016-08-17       Impact factor: 4.615

Review 4.  An update on the neurologic applications of botulinum toxins.

Authors:  Virgilio Gerald H Evidente; Charles H Adler
Journal:  Curr Neurol Neurosci Rep       Date:  2010-09       Impact factor: 5.081

Review 5.  Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.

Authors:  Wolfgang H Jost; Jörg Blümel; Susanne Grafe
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence.

Authors:  Marissa Barlaan Lukban; Raymond L Rosales; Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2009-01-14       Impact factor: 3.575

Review 7.  Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety.

Authors:  Wilhelm J Schulte-Mattler
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 8.  Understanding function and other outcomes in cerebral palsy.

Authors:  Jilda Vargus-Adams
Journal:  Phys Med Rehabil Clin N Am       Date:  2009-08       Impact factor: 1.784

Review 9.  Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.

Authors:  M R Delgado; D Hirtz; M Aisen; S Ashwal; D L Fehlings; J McLaughlin; L A Morrison; M W Shrader; A Tilton; J Vargus-Adams
Journal:  Neurology       Date:  2010-01-26       Impact factor: 9.910

10.  Adductor release and chemodenervation in children with cerebral palsy: a pilot study in 16 children.

Authors:  Abhay Khot; Samuel Sloan; Sameer Desai; Adrienne Harvey; Rory Wolfe; H Kerr Graham
Journal:  J Child Orthop       Date:  2008-06-07       Impact factor: 1.548
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.